Iquum Gets FDA OK for Flu A/B Test; Eyes More Assays for Its Automated MDx System | GenomeWeb

By Ben Butkus

Clinical diagnostic test maker Iquum this week received US Food and Drug Administration clearance for its Liat Influenza A/B assay and fully automated and integrated Liat Analyzer.

Iguum said the real-time PCR-based test — its first 510(k) win — is designed to enable clinical labs to detect and differentiate influenza A and B in about 20 minutes, or about as fast as currently used immunoassays, but with the increased sensitivity afforded by nucleic acid testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: transcriptional map of human embryo development, circadian clock genes in acute myeloid leukemia, and more.

The US National Academy of Sciences has announced 84 new members and 21 foreign associates.

The users of file-sharing site Sci-Hub work all around the globe where research is going on, Science's John Bohannon reports.

Researchers link obesity in Labrador retrievers to a deletion in their POMC gene.